Hebei Changshan Biochem Pharma (300255) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Hebei Changshan Biochem Pharma stock ¥11.69, price ¥17.39, that is 32.8% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Hebei Changshan Biochem Pharma
300255 · SHEExpensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ¥4.44 – ¥69.80 · fair‑value band ¥8.77 – ¥14.61 · the ¥17.39 price screens above the ¥11.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Hebei Changshan Biochem Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally.
Show moreShow less
It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide.
The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services.
It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.
Stock analysis
Hebei Changshan Biochem Pharma (300255) currently trades at ¥17.39, while our estimate is ¥11.69, 33% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ¥8.77 (bear) to ¥14.61 (bull), the price of ¥17.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Hebei Changshan Biochem Pharma reported revenue of 875M CNY in FY2025 versus 3.0B CNY in FY2021, a compound −26.3%/yr. Reported net income was −358M CNY in FY2025.
Key figures
Market cap 16.0B CNY (≈ $2.4B) Mid · P/S ratio 19.5 · EPS (TTM) ¥−0.3800 · Dividend yield 0.7% · Net margin −37.7% · Return on equity −27.4% · Return on assets (EBIT) −5.8% (5-year average) · Operating margin 7.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (medium confidence).
What moves the price
The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, 300255 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Hebei Changshan Biochem Pharma with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Stock screener with 62 metrics
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 300255 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 300255 |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs 300255 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 300255 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 300255 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 300255 |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs 300255 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 300255 |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs 300255 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 300255 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Hebei Changshan Biochem Pharma (300255) overvalued or undervalued?
What is the fair value of 300255?
What is the quality score of 300255?
What is the price target for Hebei Changshan Biochem Pharma (300255)?
What is the Hebei Changshan Biochem Pharma stock forecast for 2026?
What is the revenue of Hebei Changshan Biochem Pharma (300255)?
Does Hebei Changshan Biochem Pharma pay a dividend?
How much is the dividend of Hebei Changshan Biochem Pharma (300255)?
What is the intrinsic value of Hebei Changshan Biochem Pharma (300255)?
Is Hebei Changshan Biochem Pharma stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 300255?
How much is Hebei Changshan Biochem Pharma worth?
What do the bullish and bearish scenarios say about 300255?
How solid is the balance sheet of Hebei Changshan Biochem Pharma (300255)?
How far is 300255 from its 52-week high?
Which stocks are comparable to Hebei Changshan Biochem Pharma?
Is Hebei Changshan Biochem Pharma stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Hebei Changshan Biochem Pharma (300255)?
What should I pay attention to with Hebei Changshan Biochem Pharma right now?
Key figures of Hebei Changshan Biochem Pharma
How large is the market capitalisation of Hebei Changshan Biochem Pharma (300255)?
What is the P/S ratio of Hebei Changshan Biochem Pharma (300255)?
What are the earnings per share of Hebei Changshan Biochem Pharma (300255)?
What is the dividend yield of Hebei Changshan Biochem Pharma (300255)?
What is the net margin of Hebei Changshan Biochem Pharma (300255)?
What is the return on equity of Hebei Changshan Biochem Pharma (300255)?
What is the EBIT return on assets of Hebei Changshan Biochem Pharma (300255)?
What is the operating margin of Hebei Changshan Biochem Pharma (300255)?
How fast is revenue growing at Hebei Changshan Biochem Pharma (300255)?
How fast are earnings growing at Hebei Changshan Biochem Pharma (300255)?
How much free cash flow does Hebei Changshan Biochem Pharma (300255) generate?
How much net debt does Hebei Changshan Biochem Pharma (300255) carry?
Watch Hebei Changshan Biochem Pharma in the live analysis
One click puts Hebei Changshan Biochem Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.